Maravai LifeSciences Holdings, Inc. (MRVI) Income Statement
MRVI 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsMRVI revenue and net income
Where MRVI's revenue goes
2025Each bar shows an amount and its share of revenue. MRVI kept −70.4% of revenue as net income.
MRVI profit margins
MRVI growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −28.3% | −40.5% | −8.1% | — |
| Gross profit | −69.2% | −64.0% | −30.4% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MRVI quarterly EPS vs estimates
Maravai LifeSciences beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.08).
MRVI income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $185.7M | $259.2M | $288.9M | $883.0M | $799.2M | $284.1M | $143.1M | $123.8M |
| Cost of revenue | $152.4M | $150.9M | $148.7M | $169.0M | $140.6M | $79.6M | $66.8M | $60.8M |
| Gross profit | $33.4M | $108.3M | $140.2M | $714.0M | $658.7M | $204.4M | $76.3M | $63.1M |
| Research & development | $23.3M | $19.2M | $17.3M | $18.4M | $15.2M | $9.3M | $3.6M | $4.5M |
| Sales, general & admin | $145.1M | $161.8M | $150.1M | $129.3M | $100.1M | $94.2M | $48.4M | $41.2M |
| Total operating expenses | $40.1M | $343.9M | $171.8M | $139.8M | $104.0M | $84.5M | $52.3M | $45.7M |
| Operating income | −$6.7M | −$235.6M | −$31.6M | $574.2M | $554.6M | $119.9M | $24.0M | $16.4M |
| Interest income | $11.4M | $27.4M | $22.6M | $2.3M | $0 | $0 | — | — |
| Interest expense | $27.0M | $47.7M | $45.9M | $20.4M | $30.3M | $30.7M | $30.0M | $27.4M |
| Income before taxes | −$235.0M | −$261.5M | $617.7M | $551.5M | $530.8M | $81.7M | −$5.9M | −$16.5M |
| Income taxes | −$4.2M | −$1.9M | $756.1M | $60.8M | $61.5M | $2.9M | −$652,000 | $417,000 |
| Net income | −$130.8M | −$144.8M | −$119.0M | $220.2M | $182.0M | $76.9M | −$8.5M | −$17.7M |
| EBITDA | −$147.5M | −$156.9M | $712.4M | $610.0M | $585.8M | $138.3M | $48.2M | $33.2M |
| EPS (diluted) | −$0.28 | −$0.16 | −$0.02 | $1.80 | $1.00 | $0.11 | −$0.09 | −$0.07 |
| Gross margin | 18.0% | 41.8% | 48.5% | 80.9% | 82.4% | 72.0% | 53.3% | 50.9% |
| Operating margin | −3.6% | −90.9% | −11.0% | 65.0% | 69.4% | 42.2% | 16.8% | 13.3% |
| Net margin | −70.4% | −55.9% | −41.2% | 24.9% | 22.8% | 27.1% | −5.9% | −14.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $51.4M | $65.8M | $49.9M | $41.6M | $47.4M | $46.9M | $56.4M | $65.2M | $73.4M | $64.2M | $74.1M | $66.9M |
| Cost of revenue | $30.8M | $32.1M | $37.6M | $36.0M | $39.6M | $39.1M | $37.4M | $36.8M | $38.3M | $38.3M | $35.1M | $36.7M |
| Gross profit | $20.6M | $33.7M | $12.2M | $5.7M | $7.8M | $7.7M | $19.0M | $28.4M | $35.1M | $25.8M | $39.0M | $30.2M |
| Research & development | $3.7M | $3.9M | $3.8M | $9.8M | $4.9M | $4.9M | $4.6M | $4.3M | $5.3M | $5.0M | $4.6M | $4.3M |
| Sales, general & admin | $32.1M | $29.1M | $31.6M | $35.4M | $38.6M | $39.6M | $41.2M | $39.1M | $40.6M | $40.9M | $38.5M | $38.9M |
| Total operating expenses | $35.7M | $31.2M | $19.0M | −$109.8M | $74.0M | $56.9M | $57.1M | $197.5M | $44.6M | $44.7M | $46.2M | $45.6M |
| Operating income | −$15.1M | $2.5M | −$6.7M | $115.4M | −$66.3M | −$49.2M | −$38.1M | −$169.1M | −$9.5M | −$18.9M | −$7.2M | −$15.4M |
| Interest income | $1.2M | $1.9M | $2.4M | $2.8M | $3.0M | $3.2M | $6.0M | $7.1M | $7.1M | $7.2M | $7.5M | $7.4M |
| Interest expense | $4.8M | $5.7M | $6.6M | $6.8M | $6.8M | $6.8M | $11.3M | $13.6M | $11.9M | $10.9M | $15.4M | $11.6M |
| Income before taxes | −$21.8M | −$6.5M | −$63.0M | −$45.1M | −$74.1M | −$52.7M | −$46.5M | −$175.6M | −$16.9M | −$22.4M | $656.2M | −$20.6M |
| Income taxes | −$171,000 | −$151,000 | $6,000 | −$92,000 | −$4.3M | $162,000 | −$7,000 | $311,000 | −$2.4M | $271,000 | $766.2M | −$5.5M |
| Net income | −$12.4M | −$3.7M | −$35.7M | −$25.6M | −$39.6M | −$29.9M | −$26.1M | −$99.0M | −$7.6M | −$12.1M | −$106.0M | −$6.5M |
| EBITDA | −$3.6M | $12.2M | −$41.7M | −$22.5M | −$51.9M | −$31.0M | −$20.7M | −$148.0M | $9.6M | $2.2M | $684.6M | $4.2M |
| EPS (diluted) | −$0.07 | $0.01 | −$0.04 | −$0.08 | −$0.08 | −$0.08 | −$0.06 | −$0.02 | −$0.06 | −$0.02 | $0.01 | −$0.01 |
| Gross margin | 40.1% | 51.2% | 24.5% | 13.6% | 16.4% | 16.5% | 33.6% | 43.5% | 47.9% | 40.3% | 52.6% | 45.1% |
| Operating margin | −29.3% | 3.8% | −13.5% | 277.3% | −139.8% | −104.9% | −67.6% | −259.4% | −13.0% | −29.4% | −9.6% | −23.1% |
| Net margin | −24.1% | −5.7% | −71.6% | −61.4% | −83.5% | −63.9% | −46.4% | −151.9% | −10.3% | −18.8% | −142.9% | −9.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MRVI's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MRVI financial results
In fiscal year 2025 (ended December 31, 2025), Maravai LifeSciences reported revenue of $185.7 million, down 28.3% from the year before. It had a net loss of $130.8 million, a net profit margin of −70.4%. Diluted earnings per share came to −$0.28. Over five years revenue grew at an average rate of −8.1% a year.
See the MRVI stock overview for the latest quote and news, or the MRVI chart for price history and technical indicators.
MRVI income statement FAQ
What is Maravai LifeSciences's annual revenue?
Maravai LifeSciences reported total revenue of $185.7 million for fiscal year 2025, which ended on December 31, 2025. That was down 28.3% from $259.2 million the previous year.
Is Maravai LifeSciences profitable?
No. Maravai LifeSciences reported a net loss of $130.8 million in fiscal 2025, a net profit margin of −70.4%; its operating margin was −3.6%.
What is Maravai LifeSciences's gross margin?
Maravai LifeSciences's gross margin was 18.0% in fiscal 2025: for every $100 of revenue, Maravai LifeSciences kept $18 after the direct cost of its products and services.
How much does Maravai LifeSciences spend on research and development?
Maravai LifeSciences spent $23.3 million on research and development in fiscal 2025, 12.6% of revenue.
How fast is Maravai LifeSciences growing?
Revenue grew −8.1% a year on average over the last five fiscal years, from $284.1 million to $185.7 million.
What are Maravai LifeSciences's earnings per share?
Maravai LifeSciences earned $-0.28 per diluted share in fiscal 2025, compared with $-0.16 a year earlier.
When will Maravai LifeSciences report its next earnings?
Maravai LifeSciences is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does Maravai LifeSciences's fiscal year end?
Maravai LifeSciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.